Furthermore, both ketamine and (S)-ketamine at doses of 10–20 mg/kg induced cognitive deficits in NMDA receptor subunit GluN2D knockout (GluN2D-KO) mice, but the same dose of (R)-ketamine did not inhibit cognitive functioning in GluN2D-KO mice (Ide et al., 2019), suggesting that, in terms of decreasing the impact on individual cognitive effects on memory, (R)-ketamine appears to have an advantage over ketamine and (S)-ketamine. The gene discussed is GRIN2D; the disease is Cognitive impairment.